文献速递心力衰竭与心肌病

恩格列净在射血分数保留的心力衰竭女性和男性中的疗效

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
PubMed 文献 · Circulation · 2022-09-13

该研究基于EMPEROR-Preserved试验,评估性别对恩格列净疗效的影响。共纳入5988例患者,女性占44.7%。结果显示,恩格列净在男女中均相似地降低心血管死亡或心衰住院风险,且改善健康状态,性别不影响疗效。

要点

  • 恩格列净在男女射血分数保留心衰患者中均降低心血管死亡或心衰住院风险。
  • 性别未改变恩格列净在不同射血分数亚组中的疗效。
  • 恩格列净在男女中均相似改善堪萨斯城心肌病问卷评分。

核心结论

  • 恩格列净在射血分数保留的心力衰竭女性和男性中产生相似的结果和健康状态获益。

研究设计与样本

  • EMPEROR-Preserved试验的性别亚组分析,共随机纳入5988例患者,女性2676例(44.7%)。

主要发现

  • 在安慰剂组中,女性全因死亡风险较低(风险比0.69,95%CI 0.56-0.84)。
  • 恩格列净降低心血管死亡或心衰住院风险在男性(风险比0.81,95%CI 0.69-0.96)和女性(风险比0.75,95%CI 0.61-0.92)中相似,交互作用P=0.54。
  • 性别未改变恩格列净与射血分数分组(41%-49%、50%-59%、≥60%)之间的疗效关系。
  • 恩格列净在男女中均相似改善堪萨斯城心肌病问卷临床总结评分(52周时男性1.38 vs 女性1.63,交互作用P=0.77)。

临床怎么用

  • 恩格列净可用于射血分数保留的心衰患者,无论男女,疗效一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Women and men with heart failure (HF) and preserved ejection fraction may differ in their clinical characteristics and their response to therapy. The aim of this study was to evaluate the influence of sex on the effects of empagliflozin in patients with HF and preserved ejection fraction enrolled in the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction). METHODS: The effects of empagliflozin on the primary outcome of cardiovascular death or hospitalization for HF and on secondary outcomes (including total HF hospitalization, cardiovascular and all-cause mortality, and Kansas City Cardiomyopathy Questionnaire scores) were compared in women and men in the overall cohort and in subgroups defined by left ventricular ejection fraction (41%-49%, 50%-59%, and ≥60%). The effects of empagliflozin on physiological measures, including changes in systolic blood pressure, uric acid, hemoglobin, body weight, and natriuretic peptide levels, were also assessed. RESULTS: Of the 5988 patients randomized, 2676 (44.7%) were women. In the placebo arm, women tended to have lower risk for adverse outcomes, including a lower risk of all-cause mortality (hazard ratio, 0.69 [95% CI, 0.56, 0.84]). Compared with placebo, empagliflozin reduced the risk of cardiovascular death or hospitalization for HF to a similar degree in both sexes (hazard ratio, 0.81 [95% CI, 0.69, 0.96] for men; and hazard ratio, 0.75 [95% CI, 0.61, 0.92] for women; Pinteraction=0.54). Sex did not modify the relationship between empagliflozin and outcomes across ejection fraction groups. Similar results were seen for secondary outcomes and physiological measures. Compared with placebo, empagliflozin improved the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score to a similar extent in both sexes (1.38 for men versus 1.63 for women at 52 weeks; Pinteraction=0.77); the results were similar for Kansas City Cardiomyopathy Questionnaire overall summary score and total summary score. CONCLUSIONS: Empagliflozin produced similar benefits on outcomes and health status in women and men with HF and preserved ejection fraction. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03057951.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Butler, Filippatos, Siddiqi, et al. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction. Circulation. 2022. PMID: 36098051. doi:10.1161/CIRCULATIONAHA.122.059755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。